Open an account

Arrowhead Pharmaceuticals

ARWR · NASDAQ

$58.92+$1.69 (+2.95%)TodayMarket closed ·
Prev close $57.23

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Employees
711
Headquarters
Pasadena, California
Listed
Dec 14, 1993
Sector
Health Care
Industry
Biotechnology
Website
arrowheadpharma.com

ARWR key statistics

Market cap
8.08B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.11M
Volume
1.74M
Open price
$56.93
High today
$59.57
Low today
$56.92
52 Week high
$95.49
52 Week low
$36.73

Arrowhead Pharmaceuticals (ARWR) at a glance

As of Oct 20, 2026, Arrowhead Pharmaceuticals (ARWR) shares are priced at $58.92, giving the company a market cap of 8.08B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $56.92 and $59.57. The current price is 3.5% above the day's low and 1.1% below its high.

Volume so far is 1.74M shares, in line with the average of 2.11M shares a day.

Over the past year Arrowhead Pharmaceuticals has ranged from $36.73 to $95.49, and now sits 38% of the way up that range.

Arrowhead Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY26 it reported -$1.36 per share against an estimate of -$1.35.

The average analyst price target is $109.27, 85.5% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

73%of 15 analyst ratings say Buy
  • Buy73.3%
  • Hold26.7%
  • Sell0.0%
Price target · 16 analystsAvg $109.27
Low
$74.74
Now
$58.92
High
$132.30

ARWR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 503.8% on average.

  1. Q4 FY24: reported -$1.37 per share against an estimate of -$1.07
  2. Q1 FY25: reported -$1.39 per share against an estimate of -$0.4464
  3. Q2 FY25: reported $2.75 per share against an estimate of -$0.202
  4. Q3 FY25: reported -$1.26 per share against an estimate of -$1.05
  5. Q4 FY25: reported -$0.18 per share against an estimate of -$0.2456
  6. Q1 FY26: reported $0.22 per share against an estimate of $0.2581
  7. Q2 FY26: reported -$0.93 per share against an estimate of -$1.21
  8. Q3 FY26: reported -$1.36 per share against an estimate of -$1.35

ARWR news

  • Vandana Singh

    Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

  • Vandana Singh

    Arrowhead Achieves Clinical Validation for New Drug Platform

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Similar companies

Companies in the same industry as Arrowhead Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.